MA46453A - Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha - Google Patents

Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha

Info

Publication number
MA46453A
MA46453A MA046453A MA46453A MA46453A MA 46453 A MA46453 A MA 46453A MA 046453 A MA046453 A MA 046453A MA 46453 A MA46453 A MA 46453A MA 46453 A MA46453 A MA 46453A
Authority
MA
Morocco
Prior art keywords
compounds useful
ifn alpha
response modulators
alpha response
imidazopyridazine compounds
Prior art date
Application number
MA046453A
Other languages
English (en)
French (fr)
Inventor
Michael E Mertzman
Steven H Spergel
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MA46453A publication Critical patent/MA46453A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
MA046453A 2016-10-07 2017-10-02 Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha MA46453A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662405309P 2016-10-07 2016-10-07

Publications (1)

Publication Number Publication Date
MA46453A true MA46453A (fr) 2019-08-14

Family

ID=60117794

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046453A MA46453A (fr) 2016-10-07 2017-10-02 Composés imidazopyridazine utiles en tant que modulateurs de réponses il-12, il-23 et/ou ifn alpha

Country Status (8)

Country Link
US (1) US10836770B2 (enExample)
EP (1) EP3523305B1 (enExample)
JP (1) JP7097875B2 (enExample)
KR (1) KR102531036B1 (enExample)
CN (1) CN110036015B (enExample)
ES (1) ES2902995T3 (enExample)
MA (1) MA46453A (enExample)
WO (1) WO2018067432A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201940483A (zh) 2018-03-12 2019-10-16 美商艾伯維有限公司 酪胺酸激酶2介導的傳訊之抑制劑
EP3849981B1 (en) 2018-09-10 2023-02-01 Eli Lilly and Company Pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives useful in the treatment of psoriasis and systemic lupus erythematosus
KR102793119B1 (ko) * 2018-09-13 2025-04-07 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 인다졸 카르복스아미드
RS66346B1 (sr) 2018-10-22 2025-01-31 Alumis Inc Inhibitori tyk2 i njihova upotreba
BR112021008675A2 (pt) 2018-11-05 2021-08-10 Syngenta Participations Ag compostos de azole-amida pesticidamente ativos
TWI800696B (zh) 2018-12-10 2023-05-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺衍生物
CA3126034A1 (en) * 2019-01-23 2020-07-30 Nimbus Lakshmi, Inc. Tyk2 inhibitors and uses thereof
WO2020182649A1 (en) 2019-03-08 2020-09-17 Syngenta Crop Protection Ag Pesticidally active azole-amide compounds
JP7549601B2 (ja) 2019-03-20 2024-09-11 シンジェンタ クロップ プロテクション アクチェンゲゼルシャフト 殺有害生物活性アゾールアミド化合物
US20220213063A1 (en) 2019-03-22 2022-07-07 Syngenta Crop Protection Ag N-[l-(5-BROMO-2-PYRIMIDIN-2-YL-1,2,4-TRIAZOL-3-YL)ETHYL]-2-CYCLOPROPYL-6-(TRIFLUOROMETHYL)PYRIDINE-4-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS INSECTICIDES
WO2020222773A1 (en) 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
CA3167313A1 (en) 2020-02-12 2021-08-19 Thomas John Bleisch Substituted 7-(methylamino)pyrazolo[1,5-a]pyrimidine-3-carboxamide derivatives
TWI810520B (zh) 2020-02-12 2023-08-01 美商美國禮來大藥廠 7-(甲基胺基)吡唑并[1,5-a]嘧啶-3-甲醯胺化合物
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
CN115916207A (zh) * 2020-08-20 2023-04-04 轶诺(浙江)药业有限公司 一类五元并六元杂环化合物及其作为蛋白受体激酶抑制剂的用途
IL301385A (en) * 2020-09-16 2023-05-01 Alumis Inc TYK2 inhibitors and their use
EP4308556A4 (en) 2021-03-16 2025-02-19 Anrui Biomedical Technology (Guangzhou) Co., Ltd. Amino heteroaryl compounds and compositions
KR20240111312A (ko) 2021-10-25 2024-07-16 카이메라 쎄라퓨틱스 인코포레이티드 Tyk2 분해제 및 이의 용도
CN116655636A (zh) * 2022-02-17 2023-08-29 上海轶诺药业有限公司 一类五元并六元杂环化合物及其作为蛋白激酶抑制剂的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
WO2009100375A1 (en) 2008-02-06 2009-08-13 Bristol-Myers Squibb Company Substituted imidazopyridazines useful as kinase inhibitors
KR20140077963A (ko) 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
ES2702126T3 (es) * 2013-12-10 2019-02-27 Bristol Myers Squibb Co Compuestos de imidazopiridazina útiles como moduladores de respuestas a IL-12, IL-23 y/o IFN alfa
KR102782807B1 (ko) * 2015-11-18 2025-03-14 브리스톨-마이어스 스큅 컴퍼니 Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 이미다조피리다진 화합물

Also Published As

Publication number Publication date
CN110036015B (zh) 2022-07-19
JP7097875B2 (ja) 2022-07-08
US20190225620A1 (en) 2019-07-25
CN110036015A (zh) 2019-07-19
ES2902995T3 (es) 2022-03-30
JP2019530699A (ja) 2019-10-24
WO2018067432A1 (en) 2018-04-12
US10836770B2 (en) 2020-11-17
KR20190057132A (ko) 2019-05-27
EP3523305A1 (en) 2019-08-14
EP3523305B1 (en) 2021-12-08
KR102531036B1 (ko) 2023-05-09

Similar Documents

Publication Publication Date Title
IL286693A (en) Modulator compounds of the integrated stress pathway, compositions comprising same and uses thereof
EP3434676A4 (en) SUBSTITUTED PYRROLOPYRIMIDINE-CDK INHIBITORS, PHARMACEUTICAL COMPOSITION THEREFOR AND USE THEREOF
IL265449A (en) Tcrs specific for minor histocompatibility (h) antigen ha-1 and uses thereof
EP3377657A4 (en) TRANSFORMABLE MARKING COMPOSITIONS, METHODS AND METHODS THEREWITH
HUE053737T2 (hu) Piridopirrolokinoxalin vegyületek, készítményeik és alkalmazásaik
MA46620A (fr) Composés hétérobicycliques utiles en tant que modulateurs de réponses à il-12, il-23 et/ou ifn alpha
BR112017008666A2 (pt) anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
EP3411411A4 (en) BENZOPYRAZOL COMPOUNDS AND ANALOGUE THEREOF
HUE060182T2 (hu) Szomatosztatin modulátorok és azok felhasználása
EP3538071A4 (en) PHARMACEUTICAL COMPOUNDING METHODS AND SYSTEMS
ITUB20153129A1 (it) Composizione elastomerica comprendente grafene e componenti di pneumatico comprendenti detta composizione.
EP3428171A4 (en) CONNECTION AND COLOR TRANSFORMATION FILM THEREWITH
EP3528813A4 (en) P2X3 AND / OR P2X2 / 3 CONNECTIONS AND METHOD
EP3542358A4 (en) SYSTEM FOR MIXED REALITY WITH PRESENTATION WITH REDUCED PERFORMANCE
EP3456767A4 (en) RUBBER COMPOSITION AND AIR TIRES USED THEREOF
EP3467033A4 (en) POLYCARBONATE COMPOSITION AND ARTICLES THEREWITH
EP3353533A4 (en) QUANTUM POINT SAFETY INKS
EP3450444A4 (en) CROCINE COMPOUNDS AND USES THEREOF
EP3328912A4 (en) POLYURETHANE (METH) ACRYLATOLIGOMERS AND HARDENABLE COMPOSITIONS USING THESE OLIGOMERS
EP3473677A4 (en) CURABLE POLYORGANOSILOXAN COMPOSITION AND USE THEREOF
MA44772A (fr) 6-aminopyridine-3-yl thiazoles utilisés en tant que modulateurs de ror t
EP3328368A4 (en) COMPOUNDS AND PHARMACEUTICAL COMPOSITION RELATING TO THE UBIQUITINATION PROTEASOM SYSTEM
EP3453705A4 (en) PHOTOISOMERE CONNECTIONS AND DEVICE THEREFOR
EP3321535A4 (en) DISC BRAKE DEVICE
EP3347884A4 (en) PRIVACY-MAINTENANCE MONITORING